175 related articles for article (PubMed ID: 19661622)
1. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease.
Popp J; Lewczuk P; Linnebank M; Cvetanovska G; Smulders Y; Kölsch H; Frommann I; Kornhuber J; Maier W; Jessen F
J Alzheimers Dis; 2009; 18(4):819-28. PubMed ID: 19661622
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta.
Oikonomidi A; Lewczuk P; Kornhuber J; Smulders Y; Linnebank M; Semmler A; Popp J
J Neurochem; 2016 Oct; 139(2):324-332. PubMed ID: 27507672
[TBL] [Abstract][Full Text] [Related]
3. Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease.
Arlt S; Schwedhelm E; Kölsch H; Jahn H; Linnebank M; Smulders Y; Jessen F; Böger RH; Popp J
J Alzheimers Dis; 2012; 31(4):751-8. PubMed ID: 22710910
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
5. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
6. One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond.
Dayon L; Guiraud SP; Corthésy J; Da Silva L; Migliavacca E; Tautvydaitė D; Oikonomidi A; Moullet B; Henry H; Métairon S; Marquis J; Descombes P; Collino S; Martin FJ; Montoliu I; Kussmann M; Wojcik J; Bowman GL; Popp J
Alzheimers Res Ther; 2017 Jun; 9(1):43. PubMed ID: 28623948
[TBL] [Abstract][Full Text] [Related]
7. Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid.
Obeid R; Kasoha M; Knapp JP; Kostopoulos P; Becker G; Fassbender K; Herrmann W
Clin Chem; 2007 Jun; 53(6):1129-36. PubMed ID: 17384003
[TBL] [Abstract][Full Text] [Related]
8. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
[TBL] [Abstract][Full Text] [Related]
9. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
10. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
11. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
Toledo JB; Zetterberg H; van Harten AC; Glodzik L; Martinez-Lage P; Bocchio-Chiavetto L; Rami L; Hansson O; Sperling R; Engelborghs S; Osorio RS; Vanderstichele H; Vandijck M; Hampel H; Teipl S; Moghekar A; Albert M; Hu WT; Monge Argilés JA; Gorostidi A; Teunissen CE; De Deyn PP; Hyman BT; Molinuevo JL; Frisoni GB; Linazasoro G; de Leon MJ; van der Flier WM; Scheltens P; Blennow K; Shaw LM; Trojanowski JQ;
Brain; 2015 Sep; 138(Pt 9):2701-15. PubMed ID: 26220940
[TBL] [Abstract][Full Text] [Related]
13. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
Popp J; Lewczuk P; Frommann I; Kölsch H; Kornhuber J; Maier W; Jessen F
J Alzheimers Dis; 2010; 22(2):459-68. PubMed ID: 21084733
[TBL] [Abstract][Full Text] [Related]
15. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
16. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
[TBL] [Abstract][Full Text] [Related]
17. Onset of Preclinical Alzheimer Disease in Monozygotic Twins.
Konijnenberg E; Tomassen J; den Braber A; Ten Kate M; Yaqub M; Mulder SD; Nivard MG; Vanderstichele H; Lammertsma AA; Teunissen CE; van Berckel BNM; Boomsma DI; Scheltens P; Tijms BM; Visser PJ
Ann Neurol; 2021 May; 89(5):987-1000. PubMed ID: 33583080
[TBL] [Abstract][Full Text] [Related]
18. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.
Ganzer S; Arlt S; Schoder V; Buhmann C; Mandelkow EM; Finckh U; Beisiegel U; Naber D; Müller-Thomsen T
J Neural Transm (Vienna); 2003 Oct; 110(10):1149-60. PubMed ID: 14523627
[TBL] [Abstract][Full Text] [Related]
19. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
20. The transmethylation cycle in the brain of Alzheimer patients.
Mulder C; Schoonenboom NS; Jansen EE; Verhoeven NM; van Kamp GJ; Jakobs C; Scheltens P
Neurosci Lett; 2005 Sep; 386(2):69-71. PubMed ID: 16040194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
